Immune checkpoint inhibitors (ICI) have transformed cancer therapy, improving outcomes in malignancies like lung cancer, melanoma, and lymphoma by targeting PD-1, PD-L1, and CTLA-4 to enhance T cell-mediated tumor destruction. This evidence concerns the gene CTLA4 and melanoma.